We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Able Selling Assets After FDA Rejects Consent Decree Proposal
Able Selling Assets After FDA Rejects Consent Decree Proposal
September 8, 2005
The saga of troubled generic drugmaker Able Laboratories took yet another turn this month when the company said it intends to sell its assets — a move sparked by the FDA’s rejection of a consent decree proposal that would have allowed the firm to relaunch its withdrawn drug products without having to resubmit abbreviated new drug applications (ANDAs).